Breaking News, Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 10% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 3Q Revenues: $17.6 billion (+3%)   3Q Earnings: $3.0 billion (flat)   YTD Revenues: $53.0 billion (+1%)   YTD Earnings: $10.3 billion (+25%)   Comments: Pharmaceutical sales were $7.0 billion in the quarter, up 10%. Domestic sales were up 8%. International sales increased 12%. Growth was driven by Invega Sustenna/Xeplion ($324 million, +53%), Remicade ($1.7 billion, +6%), Simponi ($266 million, +44%), Stelara ($370 million, +29%), Velcade ($404 million, +24%), and Prezista...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters